RESUMO Introdução: O acidente vascular cerebral não especificado (AVC-NE) é de grande relevância nas estatísticas de mortalidade, sendo a quarta maior causa de morte no Brasil. O objetivo deste estudo foi identificar o perfil de causas reclassificadas após investigação de óbitos por AVC-NE no Brasil. Métodos: Foram selecionados todos os óbitos registrados em 2017 no Sistema de Informação sobre Mortalidade (SIM) como AVC-NE, considerados códigos garbage. As causas específicas, detectadas após investigação em 60 cidades selecionadas, foram analisadas segundo idade e sexo. Resultados: Do total de óbitos por AVC-NE das 60 cidades (n = 11.289), foram investigados 25,8%, dos quais 56,3% foram reclassificados para AVC isquêmico, 12,7% para AVC hemorrágico, e 23,3% migraram para outras causas específicas, como diabetes e doença renal crônica, em ambos os sexos. Discussão: A maior proporção de reclassificação dos óbitos por AVC-NE para AVC isquêmico em relação ao hemorrágico era esperada. No entanto, a detecção de outras causas específicas fora do grupo de AVC indica possíveis problemas de qualidade do preenchimento das causas na declaração de óbito (DO). Conclusão: As investigações realizadas permitiram identificação de subgrupos de AVC. Além da investigação, entretanto, é importante realizar capacitação com médicos para o preenchimento adequado da DO, a fim de melhorar as estimativas da mortalidade por AVC específico e possibilitar direcionamento adequado das ações e dos serviços de saúde.
1 March 2010 in European Journal of Gastroenterology & Hepatology
Objectives The activation of hepatic stellate cells (HSC) is considered the most important event in hepatic fibrogenesis. The precise mechanism of this process is unknown in autoimmune hepatitis (AIH), and more evidence is needed on the evolution of fibrosis. The aim of this study was to assess these aspects in children with type 1 AIH. Methods We analyzed 16 liver biopsy samples from eight patients, paired before treatment and after clinical remission, performed an immunohistochemical study with anti-α actin smooth muscle antibody and graded fibrosis and inflammation on a scale of 0–4 (Batts and Ludwig scoring system). Results There was no significant reduction in fibrosis scores after 24±18 months (2.5±0.93 vs. 2.0±0.53, P=0.2012). There was an important decrease in inflammation: portal (2.6±0.74 vs. 1.3±0.89, P=0.0277), periportal/periseptal (3.0±0.76 vs. 1.4±1.06, P=0.0277), and lobular (2.8±1.04 vs. 0.9±0.99, P=0.0179). Anti-α actin smooth muscle antibodies were expressed in the HSC of the initial biopsies (3491.93±2051.48 μm2), showing a significant reduction after remission (377.91±439.47 μm2) (P=0.0117). Conclusion HSC activation was demonstrated in the AIH of children. The reduction of this activation after clinical remission, which may precede a decrease in fibrosis, opens important perspectives in the follow-up of AIH.
To study the effect of short-chain fatty-acids on atrophy and inflammation of excluded colonic segments before and after the development of diversion colitis. Diversion colitis is a chronic inflammatory process affecting the dysfunctional colon, possibly evolving with mucous and blood discharge. The most favored hypotheses to explain its development is short-chain fatty-acid deficiency in the colon lumen. Wistar rats were submitted to colostomy with distal colon exclusion. Two control groups (A1 and B1) received rectally administered physiological saline, whereas two experimental groups (A2 and B2) received rectally administered short-chain fatty-acids. The A groups were prophylactically treated (5th to 40th days postoperatively), whereas the B groups were therapeutically treated (after post-operative day 40). The mucosal thickness of the excluded colon was measured histologically. The inflammatory reaction of the mucosal lamina propria and the lymphoid tissue response were quantified through established scores. There was a significant thickness recovery of the colonic mucosa in group B2 animals (p = 0.0001), which also exhibited a significant reduction in the number of eosinophilic polymorphonuclear cells in the lamina propria (p = 0.0126) and in the intestinal lumen (p = 0.0256). Group A2 showed no mucosal thickness recovery and significant increases in the numbers of lymphocytes (p = 0.0006) and eosinophilic polymorphonuclear cells in the lamina propria of the mucosa (p = 0.0022). Therapeutic use of short-chain fatty-acids significantly reduced eosinophilic polymorphonuclear cell numbers in the intestinal wall and in the colonic lumen; it also reversed the atrophy of the colonic mucosa. Prophylactic use did not impede the development of mucosal atrophy.